Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (375 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 25 Mar 2025 – 20 Aug 2026, limited by HDFC Nifty Top 20 Equal Weight Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC Nifty Top 20 Equal Weight Index Fund | Nifty 500 |
|---|---|---|
| 25 Mar 2025 | ₹100.00 | ₹100.00 |
| 07 May 2025 | ₹102.37 | ₹102.96 |
| 19 Jun 2025 | ₹103.74 | ₹106.18 |
| 31 Jul 2025 | ₹102.50 | ₹106.89 |
| 12 Sep 2025 | ₹105.93 | ₹108.17 |
| 25 Oct 2025 | ₹109.24 | ₹110.49 |
| 07 Dec 2025 | ₹111.41 | ₹111.18 |
| 18 Jan 2026 | ₹109.19 | ₹109.55 |
| 02 Mar 2026 | ₹104.70 | ₹106.52 |
| 14 Apr 2026 | ₹99.47 | ₹103.46 |
| 27 May 2026 | ₹98.28 | ₹107.14 |
| 08 Jul 2026 | ₹99.08 | ₹106.86 |
| 20 Aug 2026 | ₹102.99 | ₹109.68 |
| Metric | HDFC · Direct NAV ₹10.30 Very High risk ★★☆☆☆ 1Y | Category median Index Funds · 375 funds |
|---|---|---|
| -1.81% | +5.66% | |
| — | +8.82% | |
| — | +9.15% | |
| — | +11.72% | |
| +2.12% | +7.67% | |
| -1.24% | — | |
| — | +12.67% | |
| — | +13.64% | |
| — | +12.84% | |
| Risk | ||
| 13.57% | 13.97% | |
| -0.61 | 0.24 | |
| -0.85 | 0.36 | |
| -16.07% | -16.12% | |
| Nifty 500 | — | |
| — | +0.84% | |
| — | 1.00 | |
| — | 102.2% | |
| — | 97.2% | |
| 0.37% | 0.36% | |
| ₹84.92Cr | ₹177.09Cr | |
| None | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 47% | 35% | |
| Arun Agarwal | — | |
| 25 Mar 2025 | — | |
| 20 | — | |
| 50.9% | — | |
| 0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.